Novartis has nabbed the U.S. Food and Drug Administration’s breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a tough-to-treat mutated lung cancer type.
Novartis aims to file for U.S. approval for oral capmatinib later this year as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), the Basel-based company said on Friday.
Pfizer drug Xalkori in 2018 also won the FDA’s fast-track development and review designation for this form of lung cancer for which there is not yet an approved targeted therapy.
Drugmakers like Novartis and Pfizer are increasing using biomarker-driven drugs to treat patients with rare tumours — only about 3%-4% of lung cancer patients have the MET exon14 skipping mutation — that have proven very difficult for oncologists to fight with their existing arsenal of medicines.
“We look forward to working with the FDA and global health authorities to bring capmatinib to patients who currently have no available targeted therapy options,” said John Tsai, Novartis’s chief drug developer.
The FDA’s breakthrough therapy tag is meant to speed the development and review of drugs aimed at life-threatening conditions that may boost the standard of care.
By John Miller
NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.
The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.
BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.